Clinical studies with MTA

British Journal of Cancer

Volumn 78, Issue SUPPL. 1, 1998, Pages 35-40

  Calvert, A H ^a   Walling, J M ^b  

^a NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Antimetabolite; Clinical trial; LY231514; MTA; Multi targeted antifolate

Indexed keywords

AMINOTRANSFERASE; CISPLATIN; DIHYDROFOLATE REDUCTASE; FLUOROURACIL; FOLIC ACID; FOLIC ACID ANTAGONIST; GEMCITABINE; LOMETREXOL; PEMETREXED; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; THYMIDYLATE SYNTHASE; THYMIDYLATE SYNTHASE INHIBITOR;

ANEMIA; BLADDER CANCER; BREAST CANCER; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; DERMATITIS; DRUG MECHANISM; DRUG STRUCTURE; ENZYME DEFECT; ENZYME INHIBITION; FATIGUE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PANCREAS CANCER; PRIORITY JOURNAL; RASH; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUTAMATES; GUANINE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS;

EID: 0031875546     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.752     Document Type: Article

References (34)

1. Beardsley GP, Moroson BA, Taylor EC and Moran RG (1989) A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis. J Biol Chem 264: 26-30
2. Burris H, Von Hoff D, Bowen K, Heaven R, Rinaldi D, Eckardt J, Fields S, Campbell L, Robert F, Patton S and Kennealey G (1994) A phase II trial of ZD1694, a novel thymidylate synthase inhibitor, in patients with advanced non-small cell lung cancer. Annals Oncol 5 (Suppl 5): 133, A244
3. Calvert AH, Jones TR, Dady PJ, Grzelakowska-Sztabert B, Paine RM, Taylor GA and Harrap KR (1980) Quinazoline antifolates with dual biochemical loci of action. Biochemical and biological studies directed towards overcoming methotrexate resistance. Eur J Cancer 16: 713-722
4. 10-propargyl-5,8-dideazafolic acid. J Clin Oncol 4(8): 1245-1252
5. Clarke S, Boyer M, Milward M, Findlay M, Ackland S, Childs A, Brew S and Walcher V (1997) Phase II study of LY231514, A multitargated antifolate (MTA), in patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 16: 465: A1670
6. Comis R, Kris MG, Lee JS, Gralla RJ, Shridhar K, Crawford J, Batist G, Wernz J, Belani C, Vokes E, Einzig A, Grunberg SE, Niedhart J, Blumenreich M, Maurer H, Evans W (1994) Multicenter, randomized trials in 673 comparing the combination of edatrexate mitomycin and vinblastine (EMV) with mitomycin and vinblastine (MV) in patients with stage IIIB and IV non-small cell lung cancer. Lung Cancer 11 (suppl 1): 119
7. Crawford J, O'Rourke M, Schiller JH, Harris Spiridonitis C, Yanovich S, Ozer H, Langleben A, Hutchins L, Koletsky A, Clamon G, Burman S, White R and Hohneker J (1996) Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer. J Clin Oncol 14(10): 2274-2784
8. Cripps MC, Burnell M, Jolivet J, Lofters W, Fisher B, Panasci L, Iglesias J and Eisenhauer E (1997) Phase II study of a multi-targeted antifolate (LY231514) (MTA) as first-line therapy in patients with locally advanced or metastatic colorectal cancer (MCC). Proc Am Soc Clin Oncol 16: 267: A949
9. Farber S, Diamond LK, Mercer RD, Sylvester RF and Wolff JA (1948) Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (aminopterin). N Eng J Med 238: 787-793
10. Faries D (1994) Practical modifications of the continual reassessment method for phase I cancer trials. J Biopharm Stat 4: 147-164
11. Gorlick R, Goker E, Trippett T, Waltham M, Banerjee D and Bertino JR (1996) Intrinsic and acquired resistance to methotrexate in acute leukemia. Drug Ther 335: 1041-1048
12. John W, Clark J, Burris H, Picus J, Schulman L, Thornton D and Lochrer P (1997) A phase II trial of LY231514 in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 16: 292: A1038
13. Jolivet J, Cowan KH and Curt GA (1983) The pharmacology and clinical use of methotrexate. N Engl J Med 309: 1094-1104
14. Kris MG, D-Acquisto RW, Gralla RJ, Burke MT, Marks LD, Fanucchi MP and Heelan RT (1989) Phase II trial of trimetrexate in patients with stage III and IV non-small-cell lung cancer. Am J Clin Oncol 12(1): 24-26
15. Lee JS, Libshitz HI, Murphy WK, Jeffries D and Hong WK (1990) Phase II study of 10-ethyl-10-deaza-aminopterin (10-EdAM; CGP 30 694) for stage IIIB or IV non-small cell lung cancer. Invest New Drugs 8(3): 299-304
16. McDonald AC, Vasey PA, Walling J, Lind MJ, Bailey NP, Siddiqui N, Twelves C, Cassidy J and Kaye SB (1996) Phase I and pharmacokinetic study of LY231514, the multitargeted antifolate, administered by daily x 5 q 21 schedule. Annals Oncol 7(Suppl 5): 126: A608
17. Miller KD, Loehrer PJ, Picus J, Blanke C, John W, Clark J, Shulman L, Burris H, Thornton D (1997) A phase II trial of LY231514 in patients with unresectable pancreatic cancer. Proc Am Soc Clin Oncol 16: 297: A1060
18. 10-propargyl-5,8-dideazafolic acid. Cancer Research 52: 1137-1143
19. Rinaldi DA, Burris HA, Dorr FA, Woodworth JR, Kuhn JG, Eckardt JR, Rodriguez G, Corso SW, Fields SM, Langely C, Clark G, Faries D, Lu P and Von Hoff DD (1995) Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. J Clin Oncol 13: 2842-2850
20. Rinaldi DA, Burris HA, Dorr FA, Rodriguez G, Eckhardt SG, Fields SM, Woodworth JR, Kuhn JG, Langley C, Clark G, Lu P and Von-Hoff DD (1996) A phase I evaluation of LY231514, a novel multitargeted antifolate, administered every 21 days. Proc Am Soc Clin Oncol 15: 489
21. Rusthoven J, Eisenhauer E, Butts C, Gregg R, Dancey J, Fisher B and Iglesias J (1997) A phase II study of the multi-targeted antifolate LY231514 in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 16: 480: A1728
22. Schultz RM, Andis SL, Bewley JR, Chen VJ, Habeck LL, Mendelsohn LG, Patel VF, Rutherford PG, Self TD, Shih C, Theobald KS, Worzalla JF, Houghton PJ (1996) Antitumor activity of the multitargeted antifolate LY231514. Proc Am Assoc Clin Res 37: 380
23. Shih C, Chen VJ, Gossett LS, Yates SB, MacKellar WC, Habeck LL, Shackelford KA, Mendelshohn LG and Soose DJ (1997) LY231514, a pyrrolo[2,3-d]pyrimidine based antifolate that inhibits multiple folate requiring enzymes. Canc Res 57: 1116-1123
24. Shum KY, Kris MG, Gralla RJ, Burke MT, Marks LD and Heelan RT (1988) Phase II study of 10-ethyl-10-deaza-aminopterin in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 6(3): 446-450
25. Smith IE, Miles DW, Coleman RE, Lind MJ, McCarthy S and Chick J (1997) Phase II study of LY231514 (MTA) in patients (pts) with locally recurrent or metastatic breast cancer (LR/MBC) - an interim report. Proc Am Soc Clin Oncol 16: 191: A671
26. Souhami RL, Rudd RM, Spiro SG, Allen R, Lamond P and Harper PG (1992) Phase II study of edatrexate in stage III and IV non-small cell lung cancer. Cancer Chemother Pharmacol 30: 465-468
27. Taylor EC, Kuhnt D, Shih C, Rinzel SM, Grindey GB, Barredo J, Jannatipour M and Moran RG (1992) A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-(4-(2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl) benzoyl)-L-glutamic acid, is an inhibitor of thymidylate synthase. J Med Chem 35: 4450-4454
28. Thoedtmann R, Kemmerich M, Depenbrock H, Blatter J, Ohnmacht U, Rastetter J, Hanauske AR (1997) A phase I study of MTA (multi-targeted antifolate, LY231514) plus cisplatin (cis) in patients with advanced solid tumours. Eur J Cancer 33 (suppl 8): S247
29. Thymidylate Synthase Inhibitor LY 231514. Clinical Investigation Brochure. Lilly Research Laboratories, Indianapolis, IN, Eli Lilly & Co, May 1992.
30. Tonkinson JL, Wagner MM, Paul DC, Gates SG, Marder P, Mendelsohn LG and Williams DC (1996) Cell cycle modulation by the multitargeted antifolate, LY231514, increases the antiproliferative activity of gemcitabine. Proc Am Assoc Cancer Res 37: 370
31. Von Hoff DD (1988) Human tumor cloning assays: Applications in clinical oncology and antineoplastic agent development. Cancer Met Reviews 7: 357-371
32. Ward WHJ, Kimbell R and Jackman AL (1992) Kinetic characteristics of ICI D1694: A quinazoline antifolate which inhibits thymidylate synthase. Biochem Pharmacol 43: 2029-2031
33. Woodworm J, Rinaldi D, Burris H, Thornton D, Reddy S, Kuhn J and Von Hoff D (1997) Assessments of hemotoxicity and relationships to pharmacokinetics from a LY23514 phase I study. Proc Am Soc Clin Oncol 16: 734: 210a
34. Worzalla JF, Self TD, Theobald KS, Schultz RM, Mendelsohn LG and Shih C (1997). Effects of folic acid on toxicity and antitumor activity of LY231514 multi-targeted antifolate (MTA). Proc Am Assoc Cancer Res 38: 478